A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE) is a PHASE3 clinical asset sponsored by Eidos Therapeutics, a BridgeBio company in Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis. SEO and diligence focus: Acoramidis (AG10), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Amyloidosis in Transthyretin (TTR)
Modality: small molecule
Target: Acoramidis (AG10)
Sponsor: Eidos Therapeutics, a BridgeBio company
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Acoramidis (AG10)
View original source fields
Condition raw: Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis
Condition normalized: Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy, Transthyretin-Related, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Heart Disease, Cardiomyopathies, Amyloidosis, Hereditary, Transthyretin-Related, Polyneuropathies, Amyloidosis
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Acoramidis (AG10)
Target normalized: Acoramidis (AG10)